Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 1998

View Archived Issues

ZymeTx signs agreement for potential HIV antiviral technology

Enzo Biochem initiates phase I clinical trials of HIV-1 treatment

Generex submits IND for Oralin in Canada

New clinical trial of G-3139 in prostate cancer gets under way at U.S. center

NeXstar initiates third phase II MiKasome trial

Increased sexual activity in Muse-treated men does not mean increased risk of CV side effects

Ribi acquires new adjuvant technology from U of Nebraska

Promising phase II results reported for BTI-322 in GVHD

StressGen establishes multiinstitutional collaboration for stress protein-modulating drugs

Arylureas and arylmethylcarbamoyl derivatives as ACAT inhibitors

Antimetastatic antibiotic isolated from Penicillium at Takara Shuzo

Potent, broad-spectrum antibacterial compounds developed at Daiichi

Yoshitomi prepares agents for hyperuricemia and gout

Antifungal series emerges from R&D at Pola

Profile of the second-generation alkylphosphocholine perifosine

RiboGene receives additional funding in the area of antifungals

Altana offer to license Solarase accepted by Hyal

Joint development agreement for Hyanalgese-D announced by Hyal

Xoma now owns or has exclusive rights to all BPI-related patents

Restless legs syndrome: description and treatment options

Hypnotic effects of the benzodiazepine receptor ligand SX-3228 in rats

Calcium channel blockers reduce craving for alcohol

SIB-1553A goes head-to-head with established cognition-enhancing drugs

HMR arthritis Rx up for FDA committee review

EEG analysis reveals the atypical antipsychotic profile of OPC-14597

New indication explored for established anticonvulsant

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...